<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63721">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01854437</url>
  </required_header>
  <id_info>
    <org_study_id>1391</org_study_id>
    <nct_id>NCT01854437</nct_id>
  </id_info>
  <brief_title>The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for
      control of Hyperphosphatemia are used.  The aim of this study was to assess the effect of
      magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of
      its side effects in hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>plasma phosphate level</measure>
    <time_frame>4 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Mg Oxide</arm_group_label>
    <description>Mg Oxide (Mg速, 21st Century速) 250 mg orally for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>placebo 1 tab TDS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mg Oxide</intervention_name>
    <description>250 mg orally for 4 weeks</description>
    <arm_group_label>Mg Oxide</arm_group_label>
    <other_name>(Mg速, 21st Century速)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hemodialysis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        hemodialysis with duration&gt;3 months serum P level &gt;5.5 mg/dl serum Ca&gt;8 mg/dl.

        Exclusion Criteria:

        Mg level &gt;3 mg/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shiraz University Hemodialysis Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>o98-711</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 12, 2013</lastchanged_date>
  <firstreceived_date>May 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Maryam Pakfetrat</investigator_full_name>
    <investigator_title>associated professor of shiraz Shiraz University of Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>mg oxide</keyword>
  <keyword>hyperphosphatemia</keyword>
  <keyword>plasma phosphor level</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
